Elevance (ELV) stock thrives with fee-based plans, preventive care, and disciplined capital management, ensuring growth and strong investor returns. See more.

Baird downgraded Elevance Health (ELV) to Neutral from Outperform with a price target of $529, down from $625. The firm sees minimal ...